Table 5.
AGE-IgG is associated with the inflammatory response, whereas anti-AGE-IgG is associated with rheumatoid factor positive rheumatoid arthritis
| Serum finding | ||||
| Characteristic | IgG-AGE+ (n = 47) | IgG-AGE- (n = 191) | Anti-IgG-AGE+ (n = 65) | anti-IgG-AGE- (n = 173) |
| Females (%) | 55 | 68 | 71 | 64 |
| Age (years) | 39 ± 12 | 43 ± 14 | 41 ± 13 | 43 ± 14 |
| Swollen joint count | 8.2 ± 8.7 | 7.2 ± 8.9 | 11.0 ± 11* | 6.2 ± 7.6 |
| ESR (mm/hour) | 51 ± 38* | 36 ± 27 | 45 ± 30 | 37 ± 30 |
| CRP (md/dl) | 2.5 ± 3.1* | 1.5 ± 1.8 | 1.7 ± 2.0 | 1.8 ± 2.3 |
| Hemoglobin (mg/dl) | 13.0 ± 1.9 | 12.5 ± 1.5 | 12.7 ± 1.5 | 12.9 ± 1.6 |
| Glucose (mg/dl) | 100 ± 30 | 102 ± 40 | 99 ± 25 | 102 ± 42 |
| IgG (mg/dl) | 1427 ± 529* | 1182 ± 378 | 1252 ± 369 | 1226 ± 443 |
| IgM (mg/dl) | 139 ± 61 | 152 ± 88 | 173 ± 61* | 140 ± 88 |
| IgA (mg/dl) | 285 ± 139 | 236 ± 104 | 282 ± 126 | 232 ± 106 |
| RF+ (%) | 19 (40%) | 69 (36%) | 45 (69%)* | 25% |
| anti-AGE-IgG1+ (n) | 18 (26%) | 40 (21%) | 50 (77%) | - |
| anti-AGE-IgG3+ (n) | 12 (26%) | 38 (20%) | 49 (76%) | - |
Values are expressed as means ± SD, unless otherwise stated. *P < 0.05, by analysis of variance or χ2 test, with Yates correction where appropriate; comparisons are between AGE-IgG+ and AGE-IgG- patients, and between anti-AGE-IgG+ and anti-AGE-IgG- patients. AGE, advanced glycation end-product; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor.